Skip to main content
. 2025 Aug 22;11(34):eadx2434. doi: 10.1126/sciadv.adx2434

Fig. 4. BAY-3827 but not BAY-974 dose-dependently reverses AMPK-inhibited lipogenesis in primary hepatocytes.

Fig. 4.

(A) Representative blots of AMPKα1α2+/+ (control) hepatocytes treated with BAY-3827 and BAY-974 in basal conditions and (B) treated with 10 μM MK-8722 after compound treatment for 15 min, with selected antibodies describing AMPK signaling. (C to E) Calculated phosphorylation ratios following band intensity quantification of data from (A) and (B) showing means ± SEM from four separate experiments with n = 2 to 3 biological replicates subjected to a two-way analysis of variance (ANOVA) test with *P < 0.05 (vehicle versus treatments) and #P < 0.05 (basal versus MK-8722). (F) Lipogenesis assay of control and AMPKα1α2−/− DKO primary hepatocytes treated with BAY-3827 and inactive BAY-974, where n = 3 to 5 biological replicates from five separate experiments. A two-way ANOVA test was conducted, where *P < 0.05 (vehicle versus indicated treatment), #P < 0.05 (vehicle + MK-8722 versus in indicated treatment) and †P < 0.05 (control versus DKO treatments in basal and + MK-8722 conditions).